

# Single article describing a Randomized Controlled Trial (RCT)

**Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19 A Randomized Clinical Trial**

**Abstract**

**Importance** Ivermectin is widely prescribed as a potential treatment for COVID-19 despite uncertainty about its clinical benefit.

**Objective** To determine whether ivermectin is an efficacious treatment for mild COVID-19.

**Design, Setting, and Participants** Double-blind, randomized trial conducted at a single site in Cali, Colombia. Potential study participants were identified by simple random sampling from the state's health department electronic database of patients with symptomatic, laboratory-confirmed COVID-19 during the study period. A total of 416 adult patients with mild disease and symptoms for 7 days or fewer (at home or hospitalized) were enrolled between July 15 and November 30, 2020, and followed up through December 21, 2020.

**Intervention** Patients were randomized to receive ivermectin, 300 µg/kg of body weight per day for 5 days (n=203) or placebo (n=203).

**Main Outcomes and Measures** Primary outcome was time to resolution of symptoms within a 21-day follow-up period. Selected adverse events and serious adverse events were also collected.

**Results** Among 400 patients who were randomized in the primary analysis population (median age, 37 years; interquartile range [IQR], 29–45), 231 women (58%), 398 (99.5%) completed the trial. The median time to resolution of symptoms was 10 days (IQR, 9–13) in the ivermectin group compared with 12 days (IQR, 9–13) in the placebo group (hazard ratio for resolution of symptoms, 1.07 [95% CI, 0.87 to 1.32]; P=.33 by log-rank test). By day 21, 82% in the ivermectin group and 79% in the placebo group had resolved symptoms. The most common selected adverse event was headache, reported by 104 patients (12%) given ivermectin and 111 (56%) who received placebo. The most common serious adverse event was multistage failure, occurring in 4 patients (2 in each group).

# Collection of articles describing RCTs on the same topic

**Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19 A Randomized Clinical Trial**

**Abstract**

**Importance** Ivermectin is widely prescribed as a potential treatment for COVID-19 despite uncertainty about its clinical benefit.

**Objective** To determine whether ivermectin is an efficacious treatment for mild COVID-19.

**Design, Setting, and Participants** Double-blind, randomized trial conducted at a single site in Cali, Colombia. Potential study participants were identified by simple random sampling from the state's health department electronic database of patients with symptomatic, laboratory-confirmed COVID-19 during the study period. A total of 416 adult patients with mild disease and symptoms for 7 days or fewer (at home or hospitalized) were enrolled between July 15 and November 30, 2020, and followed up through December 21, 2020.

**Intervention** Patients were randomized to receive ivermectin, 300 µg/kg of body weight per day for 5 days (n=203) or placebo (n=203).

**Main Outcomes and Measures** Primary outcome was time to resolution of symptoms within a 21-day follow-up period. Selected adverse events and serious adverse events were also collected.

**Results** Among 400 patients who were randomized in the primary analysis population (median age, 37 years; interquartile range [IQR], 29–45), 231 women (58%), 398 (99.5%) completed the trial. The median time to resolution of symptoms was 10 days (IQR, 9–13) in the ivermectin group compared with 12 days (IQR, 9–13) in the placebo group (hazard ratio for resolution of symptoms, 1.07 [95% CI, 0.87 to 1.32]; P=.33 by log-rank test). By day 21, 82% in the ivermectin group and 79% in the placebo group had resolved symptoms. The most common selected adverse event was headache, reported by 104 patients (12%) given ivermectin and 111 (56%) who received placebo. The most common serious adverse event was multistage failure, occurring in 4 patients (2 in each group).

Summarize  
Simplify



Synthesize

The evidence suggests that ...



Assessments of output accuracy by medical domain experts